Immune checkpoint inhibitors targeting PD-1 or PD-L1, such as nivolumab and pembrolizumab, showed initial promise, particularly in second-line settings, but overall response remained suboptimal due to the immunosuppressive tumor microenvironment typical of HCC. This evidence concerns the gene CD274 and neoplasm.